A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients

被引：9

作者：

Kida, Daihei ^{[1
]}

Takahashi, Nobunori ^{[2
]}

Kaneko, Atsushi ^{[1
]}

Hirano, Yuji ^{[3
]}

Fujibayashi, Takayoshi ^{[4
]}

Kanayama, Yasuhide ^{[5
]}

Hanabayashi, Masahiro ^{[6
]}

Yabe, Yuichiro ^{[7
]}

Takagi, Hideki ^{[8
]}

Oguchi, Takeshi ^{[9
]}

Kato, Takefumi ^{[10
]}

Funahashi, Koji ^{[11
]}

Matsumoto, Takuya ^{[12
]}

Ando, Masahiko ^{[13
]}

Kuwatsuka, Yachiyo ^{[13
]}

Tanaka, Eiichi ^{[14
]}

Yasuoka, Hidekata ^{[15
]}

Kaneko, Yuko ^{[16
]}

Hirata, Shintaro ^{[17
]}

Murakami, Kosaku ^{[18
]}

Sobue, Yasumori ^{[2
]}

Nishiume, Tsuyoshi ^{[2
]}

Suzuki, Mochihito ^{[2
]}

Yokota, Yutaka ^{[2
]}

Terabe, Kenya ^{[2
]}

Asai, Shuji ^{[2
]}

Ishiguro, Naoki ^{[2
]}

Kojima, Toshihisa ^{[2
]}

机构：

[1] Nagoya Med Ctr, Dept Orthoped Surg & Rheumatol, Naka Ku, 4-1-1 Sanno Maru, Nagoya, Aichi, Japan

[2] Nagoya Univ, Nagoya Univ Hosp, Dept Orthoped Surg & Rheumatol, Grad Sch Med,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan

[3] Toyohashi Municipal Hosp, Dept Rheumatol, 50 Hakken Nishi,Aotake Cho, Toyohashi, Aichi, Japan

[4] Konan Kosei Hosp, Dept Orthoped Surg, 137 Oomatsubara, Konan, Aichi, Japan

[5] Toyota Kosei Hosp, Dept Orthoped Surg, 500-1 Ibohara,Josui Cho, Toyota, Aichi, Japan

[6] Ichinomiya Municipal Hosp, Dept Orthoped Surg, 2-2-22 Bunkyo, Ichinomiya, Aichi, Japan

[7] Tokyo Shinjuku Med Ctr, Dept Rheumatol, Shinjuku Ku, 5-1 Tsukudo Cho, Tokyo, Japan

[8] Nagoya Cent Hosp, Dept Orthoped Surg, Nakamura Ku, 3-7-7 Taiko, Nagoya, Aichi, Japan

[9] Anjo Kosei Hosp, Dept Orthoped Surg, 28 Higashihirokute, Anjo, Aichi, Japan

[10] Kato Orthoped Clin, 8-4 Minami Myoudaiji Cho, Okazaki, Aichi, Japan

[11] Kariya Toyota Gen Hosp, Dept Orthoped Surg, 5-15 Sumiyoshi Cho, Kariya, Aichi, Japan

[12] Shizuoka Kosei Hosp, Dept Orthoped Surg, Aoi Ku, 23 Kitaban Cho, Shizuoka, Japan

[13] Nagoya Univ Hosp, Dept Adv Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan

[14] Tokyo Womens Med Univ, Sch Med, Dept Rheumatol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo, Japan

[15] Fujita Hlth Univ, Dept Internal Med, Div Rheumatol, Sch Med, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi, Japan

[16] Keio Univ Hosp, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo, Japan

[17] Hiroshima Univ Hosp, Dept Clin Immunol & Rheumatol, Minami Ku, 1-2-3 Kasumi, Hiroshima, Japan

[18] Kyoto Univ, Dept Rheumatol & Clin Immunol, Grad Sch Med, Sakyo Ku, 54 Kawaharacho, Kyoto, Japan

来源：

SCIENTIFIC REPORTS | 2020年 / 10卷 / 01期

关键词：

HEALTH-ASSESSMENT QUESTIONNAIRE; CONCOMITANT METHOTREXATE; SUBCUTANEOUS ABATACEPT; INADEQUATE RESPONSE; EFFICACY; SAFETY; PROGRESSION; POSITIVITY; ADALIMUMAB; REGISTRY;

D O I：

10.1038/s41598-020-76842-4

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N=107) and ACPA-positive (N=446) groups. 'ACPA positive' was defined as >= 13.5 U/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI <= 11) at 52 weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52 weeks. Drug retention rate at 52 weeks estimated by the Kaplan-Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (Delta mTSS <= 0.5) at 52 weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.

引用

页数：9

共 50 条

[1] Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis
Hwang, Sang Mee
Kim, Jeong-Ok
Yoo, Young-Mi
Shin, Sue
Kim, Jin Q.
Park, Myoung Hee
Song, Eun Young
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (02) : 225 - 230
[2] Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry
Gottenberg, J. E.
Ravaud, P.
Cantagrel, A.
Combe, B.
Flipo, R. M.
Schaeverbeke, T.
Houvenagel, E.
Gaudin, P.
Loeuille, D.
Rist, S.
Dougados, M.
Sibilia, J.
Le Loet, X.
Marcelli, C.
Bardin, T.
Pane, I.
Baron, G.
Mariette, X.
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) : 1815 - 1819
[3] Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis
Alemao, E.
Postema, R.
Elbez, Y.
Mamane, C.
Finckh, A.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) : 455 - 466
[4] Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis
Alexiou, Ioannis
Germenis, Anastasios
Ziogas, Athanasios
Theodoridou, Katerina
Sakkas, Lazaros I.
BMC MUSCULOSKELETAL DISORDERS, 2007, 8
[5] Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis
Hagiwara, Shinya
Tsuboi, Hiroto
Terasaki, Toshihiko
Terasaki, Mayu
Toko, Hirofumi
Shimizu, Masaru
Honda, Fumika
Yagishita, Mizuki
Ohyama, Ayako
Takahashi, Hiroyuki
Yokosawa, Masahiro
Asashima, Hiromitsu
Kondo, Yuya
Matsumoto, Isao
Sumida, Takayuki
MODERN RHEUMATOLOGY, 2020, 30 (02) : 365 - 372
[6] The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis
Lv, Qianwen
Yin, Yufeng
Li, Xin
Shan, Guangliang
Wu, Xiangni
Liang, Di
Li, Yongzhe
Zhang, Xuan
PLOS ONE, 2014, 9 (02):
[7] Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis
Shidara, Kumi
Inoue, Eisuke
Tanaka, Eiichi
Hoshi, Daisuke
Seto, Yohei
Nakajima, Ayako
Momohara, Shigeki
Taniguchi, Atsuo
Yamanaka, Hisashi
RHEUMATOLOGY INTERNATIONAL, 2011, 31 (05) : 617 - 622
[8] Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis
Moghimi, Jamileh
Ghorbani, Raheb
Hasani, Farnaz
Sheikhvatan, Mehrdad
RHEUMATOLOGY INTERNATIONAL, 2013, 33 (03) : 601 - 605
[9] Impact of anti-citrullinated protein antibody on tumor necrosis factor inhibitor or abatacept response in patients with rheumatoid arthritis
Tymms, Kathleen
Butcher, Belinda
Smith, Tegan
Littlejohn, Geoffrey
EUROPEAN JOURNAL OF RHEUMATOLOGY, 2021, 8 (02) : 67 - +
[10] Value of Anti-Modified Citrullinated Vimentin and Third-Generation Anti-Cyclic Citrullinated Peptide Compared With Second-Generation Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor in Predicting Disease Outcome in Undifferentiated Arthritis and Rheumatoid Arthritis
van der Linden, Michael P. M.
van der Woude, Diane
Ioan-Facsinay, Andreea
Levarht, E. W. Nivine
Stoeken-Rijsbergen, Gerrie
Huizinga, Tom W. J.
Toes, Rene E. M.
van der Helm-van Mil, Annette H. M.
ARTHRITIS AND RHEUMATISM, 2009, 60 (08): : 2232 - 2241

← 1 2 3 4 5 →